Appointment of Broker

3 June 2011

                             Scancell Holdings Plc                             

                    (`Scancell Holdings' or the `Company')                     

                             Appointment of Broker                             

Scancell Holdings Plc, (AIM: SCLP), the developer of therapeutic cancer
vaccines is pleased to announce the appointment of XCAP Securities plc as
Broker, with immediate effect.

For further information contact:

Scancell Holdings plc               Tel: [phone]                  
                                                                               
Professor Lindy Durrant             
                                                                                         
www.scancell.com                                                               
                                                                               
Zeus Capital                        Tel: [phone]                                            
                                                                               
Nominated Advisor                                                              
                                                                               
Ross Andrews/ Tom Rowley                                                       
                                                                               
XCAP Securities plc                 Tel: [phone]                   
                                                                               
Broker                                                                         
                                                                               
John Belliss / Parimal Kumar                                                   
                                                                               
Hansard Communications Ltd          Tel: [phone]                   
                                                                               
Adam Reynolds / Guy McDougall                                                  

About Scancell

Scancell is developing novel therapeutic vaccines for the treatment of cancer
and infectious diseases based on its groundbreaking ImmunoBody® technology
platform. Scancell's first cancer vaccine SCIB1, which entered clinical trials
in 2010, is being developed for the treatment of melanoma.

Treating cancer by vaccination allows small non-toxic doses of a vaccine to be
administered to a patient, stimulating an immune response. Effective cancer
vaccines need to target dendritic cells to stimulate both parts of the cellular
immune system; the helper cell system where inflammation is stimulated at the
tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system
cells are primed to recognise and kill specific cells.

A limitation of many cancer vaccines currently in development is that they
cannot specifically target dendritic cells in vivo. Several groups have
demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing
them with tumour antigens and re-infusing them. However, this procedure is
patient specific, time consuming and expensive. Scancell has developed its
breakthrough patent protected ImmunoBody® technology to overcome these
limitations.

An ImmunoBody® is a human antibody or fusion protein engineered to express
helper cell and CTL epitopes from tumour antigens over-expressed by cancer
cells. Antibodies are ideal vectors for carrying T cell epitopes from tumour
antigens as they have long half-lives and can effectively target dendritic
cells via their Fc receptors, allowing efficient stimulation of both helper and
CTL responses.

The Immunobody® technology can be adapted to provide the basis for treating any
tumour type and may also be of potential utility in the development of vaccines
against hepatitis, HIV and other chronic infectious diseases.